By Devika Patel
Knoxville, Tenn., June 25 - Med BioGene Inc. said it completed a C$1.6 million private placement of units with a C$366,121 tranche. The company raised C$1.23 million in the first tranche on June 5.
The placement priced on April 22 for between C$1.3 million and C$1.6 million.
The company sold 15,423,488 units at C$0.08 each in the first tranche. It sold 4,576,513 units in the second tranche for a total of 20,000,001 units.
Each unit is made up of one share and a half-share purchase warrant. The whole warrants are exercisable at C$0.10 for two years. The expiration of the warrants can be accelerated if Med BioGene's stock closes above C$0.30 for 20 consecutive trading days.
Berkeley Capital Corp. II, a capital pool company, participated in the private placement as lead order, buying C$620,600 of units.
Med BioGene will use proceeds of the placement for the development and commercialization of LungExpress Dx and for general corporate purposes.
Vancouver, B.C.-based Med BioGene is a biotechnology company focused on development and commercialization of genomic-based personalized clinical laboratory diagnostic tests.
Issuer: | Med BioGene Inc.
|
Issue: | Units of one share and one half-share warrant
|
Amount: | C$1.6 million
|
Units: | 20,000,001
|
Price: | C$0.08
|
Warrants: | One half-share warrant per unit
|
Warrant expiration: | Two years
|
Warrant strike price: | C$0.10
|
Investor: | Berkeley Capital Corp. II (for C$620,600)
|
Pricing date: | April 22
|
Settlement date: | June 5 (for C$1,233,879), June 25 (for C$366,121)
|
Stock symbol: | TSX Venture: MBI
|
Stock price: | C$0.06 at close April 22
|
Market capitalization: | C$3.1 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.